Condition: Lymphoma · Sponsor: SecuraBio
The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH phenotype.
This description comes directly from the study's public registry record.
Ohad Bentur · (702) 254-0011 · TerzoMM@securabio.com
Always discuss trial participation with your own doctor first.
| Universitair Ziekenhuis Gent (UZ Gent) | Ghent, Belgium | Recruiting |
| UZ Leuven - Gasthuisberg Campus | Leuven, Belgium | Recruiting |
| Vseobecna fakultni nemocnice | Prague, Czechia | Recruiting |
| Aarhus University Hospital | Aarhus, Denmark | Recruiting |
| Rigshospitalet Copenhagen | Copenhagen, Denmark | Recruiting |
| Odense Hospital | Odense, Denmark | Recruiting |
| UNICANCER - Centre Henri-Becquerel | Rouen, Normandy, France | Recruiting |
| Institut Gustave Roussy | Villejuif, Vaillant, France | Recruiting |
| CHU Cote de Nacre | Caen, France | Recruiting |
| CHU Clermont-Ferrand | Clermont-Ferrand, France | Recruiting |
| CHU Montpellier | Montpellier, France | Recruiting |
| CHU Nantes | Nantes, France | Recruiting |
+ 32 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06522737